Bioptik TechnologyROCO:4161 68 EBITDA Margin % is 16.96% as of Dec. 2025, which is 50% above its 10-year median of 11.34. GuruFocus rates ROCO:4161 with a GF Score™ of 68/100 and a GF Value™ of NT$27.79 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Bioptik Technology ranks better than 65.48% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bioptik Technology's EBITDA for the
three
months ended in Dec. 2025 was NT$40.0 Mil. Bioptik Technology's Revenue for the
three
months ended in Dec. 2025 was NT$235.8 Mil. Therefore, Bioptik Technology's EBITDA margin for the quarter that ended in Dec. 2025 was 16.96%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bioptik Technology EBITDA Margin % Related Terms
Bioptik Technology EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bioptik Technology's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4161 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Bioptik Technology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioptik Technology EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioptik Technology's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bioptik Technology's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioptik Technology (ROCO:4161) has a EBITDA Margin % of 16.96% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioptik Technology and its competitors. This is 50% above median its historical median of 11.34. According to the industry distribution chart, Bioptik Technology ranks #282 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 34.5%.
Is Bioptik Technology's EBITDA Margin % too high?
Bioptik Technology's current EBITDA Margin % of 16.96% is 50% above median its 10-year median of 11.34. The Medical Devices & Instruments industry median EBITDA Margin % is 7.44. Bioptik Technology's value of 16.96% is 128% above this industry median. Based on the distribution chart, Bioptik Technology ranks #282 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bioptik Technology has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioptik Technology's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bioptik Technology ranks #282 out of 817 companies for EBITDA Margin %. This puts Bioptik Technology in the upper half of its industry. The industry median EBITDA Margin % is 7.44. Bioptik Technology's value of 16.96% is 128% above this benchmark. While the company's 10-year median is 11.34 vs. the industry median of 7.44, Bioptik Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioptik Technology's current EBITDA Margin % of 16.96% is 128% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioptik Technology and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioptik Technology's current EBITDA Margin % is 16.96%, which is 50% above median its own 10-year median of 11.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioptik Technology stock overvalued right now?
Based on GuruFocus' analysis, Bioptik Technology (ROCO:4161) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.79, compared to a current price of NT$23.00 — trading 17.2% below its estimated fair value. The current EBITDA Margin % is 16.96%, which is 50% above median its 10-year median of 11.34 and 128% above the Medical Devices & Instruments industry median of 7.44. Bioptik Technology's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bioptik Technology (ROCO:4161), the current EBITDA Margin % is 16.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioptik Technology (ROCO:4161) Overvalued in 2026?
Based on GuruFocus' analysis, Bioptik Technology stock appears to be undervalued.
The current stock price of NT$23.00 is trading 17.2% below its estimated GF Value™ of NT$27.79.
GuruFocus considers Bioptik Technology to be Modestly Undervalued.
Key valuation signals for ROCO:4161:
EBITDA Margin %: 16.96% (50% above median its 10-year median of 11.34)
GF Value™: NT$27.79 vs. price of NT$23.00 (17.2% below fair value)
Industry Position: 128% above the Medical Devices & Instruments median (#282 of 817)
No single metric tells the full story. See the ROCO:4161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioptik Technology Inc is a Taiwan-based company engaged in the research, development, production, and sale of medical devices and reagents. The company is also focused on developing skin care products and aims to engage in developing bioenergy, Astaxanthin, and Cellulose Bioethanol. It is involved in the business areas of Home care medical devices, Skincare- Its own brand, Dietary supplement OEM and ODM, Skincare- OEM and ODM, and Biodiesel. In the Home care business area, the company provides Easy Touch blood glucose monitoring, and blood cholesterol and uric acid monitoring systems, as well as its strips.
68GF Score
Get the complete analysis for ROCO:4161
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4161 has been successfully added to your 
